Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

DexCom (NASDAQ:DXCM – Get Free Report) had its target price increased by stock analysts at Canaccord Genuity Group from $89.00 to $99.00 in a research report issued to clients and investors on Monday, ...

Tandem Diabetes Care announced today that t:slim X2 insulin pump users in Canada can now access full compatibility with ...

AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

DexCom, Inc. (DXCM), headquartered in California, is a leading player in the medical devices sector. Valued at a market cap ...

The BNY Mellon Small/Mid Cap Growth Fund (Class A at NAV) returned 3.05% during the third quarter of 2024. Read more here.

BNY Mellon Research Growth Fund (Class A at NAV) underperformed its benchmark, the Russell 1000® Growth Index, during the ...

OK, I've been a little late coming up with my holiday gift guide, as we've already passed both Black Friday and Cyber Monday.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $90.00. The ...

The CGM market is practically a duopoly that DexCom shares with Abbott Laboratories. DexCom's success in this market explains ...